Cardiac glycosides sales in Germany are forecasted to show a decline from 2024 onwards. The sales value for 2024 is projected to be 21.9 million USD, decreasing year-on-year to 21.1 million USD in 2025, 20.3 million USD in 2026, 19.6 million USD in 2027, and finally reaching 18.9 million USD in 2028.
Year-on-year variations indicate a steady decline in sales:
- -3.65% from 2024 to 2025
- -3.79% from 2025 to 2026
- -3.45% from 2026 to 2027
- -3.57% from 2027 to 2028
Comparing the 2024 forecasted value to the actual 2023 value, there is a consistent decreasing trend for every subsequent year. The compound annual growth rate (CAGR) over the five-year period suggests an average annual decline in sales.
Future trends to watch for include advancements in alternative treatments for cardiac conditions and potential changes in insurance coverages and health policies, which could further impact the sales of cardiac glycosides. Also, the development of new drugs and patient preferences might influence the market dynamics.
